A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study updateA. van Oosterom, G. D. Demetri, Jean‐Yves Blay et al.|Journal of Clinical Oncology|2005Cited by 46